ProActive
-
ATC 2023 ProActive Study Interim Data Summary
Presented at ATC 2023, the ProActive Study interim data solidifies Prospera as a non-invasive surveillance tool
-
ProActive Study: Donor-derived cfDNA fraction levels in stable kidney transplant recipients in the first year after transplant
Presented at ATC 2023, interim ProActive Study data demonstrated that Prospera dd-cfDNA levels were persistently below 1% in 86.9% of clinically stable patients
-
ProActive Study: Elevations from baseline dd-cfDNA fraction are associated with acute allograft rejection in kidney transplant recipients
Presented at ATC 2023, interim ProActive Study data demonstrated that Prospera dd-cfDNA fraction from baseline results in kidney transplant recipients who experienced rejection (60x median elevation), clearly setting them apart from those who did not (1.3x median elevation)
-
ProActive Study: Prospera Predicted ABMR up to 4 months, TCMR up to 2 months before BPAR
Presented at ATC 2023, Prospera Kidney predicted antibody-mediated rejection (ABMR) up to four months and T cell-mediated rejection (TCMR) up to two months in advance of biopsy-proven rejection
-
ProActive Study: Dr Bromberg presents new data showing Prospera predicted ABMR up to 4 months, TCMR up to 2 months before BPAR
Listen to Dr. Jonathan Bromberg, ProActive Study's lead Investigator, discuss how Prospera™ accurately predicted ABMR and TCMR before biopsy-proven rejection, up to 4 months and 2 months in.
-
Inside the ProActive Study On Demand Series: Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update
Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update. In this episode, we discuss his:
-journey to implement cfDNA as a transplant surveillance tool
-considerations around high risk patients versus high risk situations for protocolized cfDNA care
-Approach to use cfDNA given the recent CMS article -
Inside the ProActive Study On Demand Series: Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update - Audio Only
Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update. In this episode, we discuss his:
-journey to implement cfDNA as a transplant surveillance tool
-considerations around high risk patients versus high risk situations for protocolized cfDNA care
-Approach to use cfDNA given the recent CMS article -
Inside the ProActive Study On Demand Series: Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement - Audio Only
Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement. In this episode, we discuss his:
-Clinical experience using Prospera, supported by the interim ProActive Study data
-Perspective on the recent ASTS guidelines suggesting cfDNA for surveillance use
-Advice on how interested clinicians can implement cfDNA for surveillance -
Inside the ProActive Study On Demand Series: Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement
Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement. In this episode, we discuss his:
-Clinical experience using Prospera, supported by the interim ProActive Study data
-Perspective on the recent ASTS guidelines suggesting cfDNA for surveillance use
-Advice on how interested clinicians can implement cfDNA for surveillance -
Inside the ProActive Study On Demand Series: Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use
Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use. In this episode, we discuss her:
-experience expanding protocolized use on non-study patients
-patients belief in the value of serial Prospera testing through the right education
-message to colleagues looking to begin using cfDNA/p> -
Inside the ProActive Study On Demand Series: Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use Audio - Audio Only
Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use. In this episode, we discuss her:
-experience expanding protocolized use on non-study patients
-patients belief in the value of serial Prospera testing through the right education
-message to colleagues looking to begin using cfDNA/p>